New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 8, 2013
21:06 EDTKPTIKaryopharm presents data for Selinexor at ASH
Karyopharm Therapeutics announced the oral presentation of clinical data from an ongoing Phase 1 clinical trial of its lead oral SINE compound, Selinexor, KPT-330, in patients with relapsed and/or refractory non-Hodgkin lymphoma, NHL, and chronic lymphocytic leukemia, CLL, at the 2013 American Society of Hematology, ASH, Annual Meeting and Exposition being held December 7-10 in New Orleans.The data indicate that, as of December 4, first-in-class oral Selinexor showed preliminary evidence of anti-cancer activity as a single agent in the majority of heavily pretreated relapsed and/or refractory NHL and CLL patients in the study cohort with progressive disease on study entry. In these NHL and CLL patients, Selinexor induced low levels of severe adverse events, and several of these patients have remained on study with Selinexor as their only anti-cancer treatment for more than 6-12 months.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
08:57 EDTKPTILeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
May 13, 2015
19:12 EDTKPTIOn The Fly: After Hours Movers
UP AFTER EARNINGS: Paragon Offshore (PGN), up 10.3%... Shake Shack (SHAK), up 10%... Vipshop Holdings (VIPS), up 6.7%. ALSO HIGHER: Vascular Biogenics (VBLT), up 12.8% and Oncothyreon (ONTY), up 15.5% after release of ASCO presentation data. DOWN AFTER EARNINGS: Identiv (INVE), down 10.3%... Sphere 3D (ANY), down 11.3%... VOXX International (VOXX), down 8.1%. ALSO LOWER: Puma Biotechnology (PBYI), down 21.8% after Neratinib data published in ASCO abstract... Karyopharm Therapeutics (KPTI), down 1.2% after ASCO presentation data released... Gevo (GEVO), down 11.4% after filing to sell common stock and warrants.
18:37 EDTKPTIBiopharmaceutical stocks volatile after release of ASCO presentation data
After the market close, the American Society of Clinical Oncology, or ASCO, provided public access to 5,000 cancer drug trial research abstracts ahead of the society's 51st annual meeting from May 29 to June 2 in Chicago, Illinois. In after-hours trading, a number of biopharmaceutical stocks were active, including Vascular Biogenics (VBLT) and Oncothyreon (ONTY), which rose 13% and 14.9%, respectively, and Puma Biotechnology (PBYI) and Karyopharm Therapeutics (KPTI), which fell 23.9% and 14.8%, respectively.
18:01 EDTKPTIKaryopharm down 14.8% after ASCO presentation data released
Subscribe for More Information
17:19 EDTKPTIKaryopharm to present 'encouraging' data on selinexor at 2015 ASCO meeting
Karyopharm Therapeutics announced that four abstracts describing the activity of selinexor, or KPT-330, the company's lead drug candidate in development for hematological malignancies and solid tumors, have been selected for presentation at the 2015 American Society of Clinical Oncology annual meeting, May 29 to June 2. The abstracts represent both company and investigator-sponsored clinical studies. Data to be presented include phase 2 clinical updates in both gynecologic cancers and recurrent glioblastoma, as well as phase 1b clinical data in advanced sarcomas and phase 1 clinical data in Asian patients with advanced solid and hematological cancers. "We are encouraged by the activity observed to date with selinexor in solid tumors, including the single-agent data to be presented at ASCO demonstrating durable anti-cancer activity and disease control in excess of three months across a broad range of heavily pretreated tumor-types including ovarian and endometrial cancers and advanced sarcomas. We are also particularly excited about the clear demonstration of brain penetration and anti-tumor activity of single-agent selinexor in relapsed or refractory glioblastomas," said Sharon Shacham, Chief Scientific Officer of Karyopharm.
May 11, 2015
07:18 EDTKPTIKaryopharm reports Q1 EPS (74c), consensus (73c)
Reports Q1 revenue $0, consensus $20,000.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use